ArticleFrontiers in cell and developmental biology2026
Tumor-derived sphingosine-1-phosphate shapes angiogenesis in the acidic microenvironment of osteosarcoma via paracrine and autocrine signaling.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor-associated angiogenesis is a critical driver of tumor progression and is frequently characterized by excessive branching and structural disorganization. These abnormalities arise from dynamic interactions between tumor cells and the microenvironment, where metabolic stressors such as hypoxia and extracellular acidosis promote the release of pro-angiogenic factors. Among these, sphingosine-1-phosphate (S1P) has emerged as a key bioactive lipid involved in vascular development. We previously demonstrated that acidosis promotes sphingomyelin turnover and S1P secretion in osteosarcoma cells, enhancing tumor cell survival and migration. In this study, we investigated the role of S1P in osteosarcoma-associated angiogenesis and the contribution of tumor acidosis to this process. Methods: Matrigel®-based angiogenesis assays, HUVEC cultures, 3D osteosarcoma spheroids, and microfluidic systems were employed to evaluate endothelial sprouting and tubulogenesis. S1P signaling was pharmacologically inhibited using the FDA-approved S1P modulator FTY720 (Fingolimod). Conditioned media from osteosarcoma spheroids cultured under neutral or acidic conditions were analyzed for their pro-angiogenic activity. Soluble and extracellular vesicle-associated angiogenic mediators were also assessed. Results: S1P dose-dependently impaired endothelial tubulogenesis while strongly promoting endothelial sprouting. Conditioned media derived from acid-stimulated osteosarcoma spheroids significantly increased endothelial tubule length and branching compared with conditioned media from spheroids maintained at neutral pH. These effects were markedly reduced by FTY720 treatment. Furthermore, tumor-derived S1P activated autocrine signaling in osteosarcoma cells, enhancing the secretion of soluble and extracellular vesicle-associated pro-angiogenic mediators, including bFGF and the TGF-β co-receptor Endoglin (CD105). Discussion: These findings identify a previously unrecognized acidosis-S1P axis that contributes to angiogenic remodeling in osteosarcoma. Our results highlight the multifaceted role of S1P in regulating endothelial behavior and suggest that targeting S1P signaling may represent a promising strategy to disrupt pathological neoangiogenesis in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.